| Â | Controls | 9cRA | Testosterone | Testosterone+9cRA |
|---|
Genotype | No | BrdU (%) | No | BrdU (%) | No | BrdU (%) | No | BrdU (%) |
|---|
p27+/+ | 5 | 0.3 ± 0.2 | 6 | 0.3 ± 0.2 | 5 | 0.7 ± 0.3 ** | 6 | 0.7 ± 0.3 ** |
p27+/- | 6 | 0.3 ± 0.2 | 5 | 0.5 ± 0.4 | 8 | 1.5 ± 0.6* ** | 6 | 1.4 ± 0.5* ** |
p27-/- | 6 | 0.4 ± 0.2 | 6 | 0.5 ± 0.3 | 9 | 1.7 ± 0.3* ** | 5 | 1.5 ± 0.3* ** |
- Two-month-old p27+/+, p27+/-, and p27-/- mice were treated for 7 days with: placebo (sesame oil-control group); 9cRA, 30 mg/kg body weight; testosterone, 1.0 mg/kg body weight; or combination of 9cRA + testosterone. BrdU, at 50 mg/kg body weight was injected 2 hrs prior to animal's sacrifice. BrdU-labeled cells were evaluated among epithelial cells of DLP by counting at least 500 cells per animal. Two to three levels of sectioning, 30 microns apart, were employed in some animals to reach the above number of cells. The evaluation of BrdU-labeled cells was done blindly, without knowledge of the animals' genotype and the treatment protocol. No, number of animals in each group; *, significant difference (p < 0.05) as compared to the values in p27+/+ mice; **, significant difference (p < 0.05) as compared to control values.
